Enterprise Value
271.7M
Cash
143.8M
Avg Qtr Burn
-7.327M
Short % of Float
25.18%
Insider Ownership
3.14%
Institutional Own.
32.07%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ANAVEX 2-73 (blarcamesine) (RS-002) Details Rett syndrome | Phase 3 Update | |
ANAVEX 2-73 (Blarcamesine) Details Parkinson's disease | Phase 3 Initiation | |
ANAVEX 2-73 (Blarcamesine) Details Alzheimer's disease | Phase 2/3 Update | |
ANAVEX 2-73 (blarcamesine) (2-73-RS-003) Details Rett syndrome | Phase 2/3 Update | |
ANAVEX 2-73 (blarcamesine) Details Fragile X syndrome | Phase 2/3 Initiation | |
ANAVEX 3-71 (AF710B) Details Schizophrenia | Phase 2 Initiation |